CoChat

Enriched HLA-E and CD94/NKG2A Interaction Limits Antitumor CD8+ Tumor-Infiltrating T Lymphocyte Responses

Abd Hamid, Megat, Wang, Ruo-Zheng, Yao, Xuan, Fan, Peiwen, Li, Xi, Chang, Xue-Mei, Feng, Yaning, Jones, Stephanie, Maldonado-Perez, David, Waugh, Craig, Verrill, Clare, Simmons, Alison, Cerundolo, Vincenzo, McMichael, Andrew, Conlon, Christopher, Wang, Xiyan, Peng, Yanchun, Dong, Tao · 2019 · Cancer Immunology Research
Cited by 86

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Abstract

Immunotherapy treatments with anti-PD-1 boost recovery in less than 30% of treated cancer patients, indicating the complexity of the tumor microenvironment. Expression of HLA-E is linked to poor clinical outcomes in mice and human patients. However, the contributions to immune evasion of HLA-E, a ligand for the inhibitory CD94/NKG2A receptor, when expressed on tumors, compared with adjacent tissue and peripheral blood mononuclear cells, remains unclear. In this study, we report that epithelial-derived cancer cells, tumor macrophages, and CD141+ conventional dendritic cells (cDC) contributed to HLA-E enrichment in carcinomas. Different cancer types showed a similar pattern of enrichment. Enrichment correlated to NKG2A upregulation on CD8+ tumor-infiltrating T lymphocytes (TIL) but not on CD4+ TILs. CD94/NKG2A is exclusively expressed on PD-1high TILs while lacking intratumoral CD103 expression. We also found that the presence of CD94/NKG2A on human tumor–specific T cells impairs IL2 receptor–dependent proliferation, which affects IFNγ-mediated responses and antitumor cytotoxicity. These functionalities recover following antibody-mediated blockade in vitro and ex vivo. Our results suggest that enriched HLA-E:CD94/NKG2A inhibitory interaction can impair survival of PD-1high TILs in the tumor microenvironment.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/2326-6066.cir-18-0885

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 8 references

Cited by

See all 86

Metadata

Authors
Abd Hamid, M., Wang, R.-Z., Yao, X., Fan, P., Li, X., Chang, X.-M., Feng, Y., Jones, S., Maldonado-Perez, D., Waugh, C., Verrill, C., Simmons, A., Cerundolo, V., McMichael, A., Conlon, C., Wang, X., Peng, Y., & Dong, T.
Venue
Cancer Immunology Research
Published
2019-08-01
Volume
7
Issue
8
Pages
1293-1306
ISSN
  • 2326-6066 (ISSN-L)
  • 2326-6074
OpenAlex
W2950180668
Cited by
86
References
8
FWCI
2.96
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Enriched HLA-E and CD94/NKG2A Interaction Limits Antitumor CD8+ Tumor-Infiltrating T Lymphocyte Responses. https://app.cochat.ai/papers/10.1158/2326-6066.cir-18-0885
The paper
Abd Hamid, M., Wang, R.-Z., Yao, X., Fan, P., Li, X., Chang, X.-M., Feng, Y., Jones, S., Maldonado-Perez, D., Waugh, C., Verrill, C., Simmons, A., Cerundolo, V., McMichael, A., Conlon, C., Wang, X., Peng, Y., & Dong, T. (2019). Enriched HLA-E and CD94/NKG2A Interaction Limits Antitumor CD8+ Tumor-Infiltrating T Lymphocyte Responses. Cancer Immunology Research. https://doi.org/10.1158/2326-6066.cir-18-0885

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.